The study explores prevention measures for group B streptococcal disease in various populations, suggesting new vaccine development.
Group B streptococcus commonly colonizes the human gastrointestinal and genitourinary tracts and is the single most common bacterial cause of invasive infection among newborns in the United States. Intrapartum antibiotic prophylaxis is currently used to reduce the risk of group B streptococcal disease among pregnant persons and newborns. No strategies are currently available to prevent disease in later infancy or among nonpregnant adults. Vaccines against group B streptococcal disease that consist of capsular polysaccharides linked to protein antigens are in development and may provide a means of prevention for all at-risk populations.
No takes yet. Share an insight, caveat, or question.
Karen M. Puopolo (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: